Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257426 · ClinicalTrials.gov registry record · Phase 2
Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00257426 is a Phase 2 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 31 participants.
The verdict
NCT00257426, a Phase 2 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Octreotide may stop or slow the growth of tumor cells and may be an effective treatment for liver cancer. PURPOSE: This phase II trial is studying how well octreotide works in treating patients with locally advanced or metastatic liver cancer.
Interventions
- DRUG octreotide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257426
The ClinicalTrials.gov registry entry for NCT00257426 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which octreotide acetate is the first listed.
NCT00257426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257426 about?
NCT00257426 is a clinical study titled "Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer". RATIONALE: Octreotide may stop or slow the growth of tumor cells and may be an effective treatment for liver cancer. PURPOSE: This phase II trial is studying how well octreotide works in treating patients with locally advanced or metastatic liver cancer.
What is the current status of trial NCT00257426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2005-07. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00257426?
The interventions under investigation include: octreotide acetate (DRUG).
Who is sponsoring clinical trial NCT00257426?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.